Remove partners-program
article thumbnail

Why Omada’s CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program

MedCity News

Omada Health is its first partner. CEO Sean Duffy said his company stood out from the many other virtual diabetes care companies out there because about 20 million Americans — many of whom shop on Amazon — are eligible for Omada’s programs.

96
article thumbnail

Amid strategic pivot, 2seventy bio plots comeback for BMS-partnered CAR-T Abecma

Fierce Pharma

Now, the company is splitting in two once again, passing its R&D programs to Regeneron and going all-in on its Bristol Myers Squibb-partnered CAR-T Abecma. . | 2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies.

246
246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Janssen, Johns Hopkins Partner on Dermatology Ethnic Skin Program

PharmExec

Janssen, Johns Hopkins Dermatology’s Ethnic Skin Fellowship Program partnership focuses on improving clinical care and advancing research in for skin-of-color patients.

article thumbnail

Payer Insights Program Highlights How Payers and Tech Partners Are Thinking About AI, Health Equity, and the Consumer Experience [Sponsored]

MedCity News

HLTH 2023 introduced a new program focused on technology trends for and perspectives from payers in a series of conversations around AI, health equity and healthcare innovation.

article thumbnail

Gilead’s $285M Confidence Vote for Next-Gen Cancer Med & New Cell Therapy Tech

MedCity News

Gilead Sciences is increasing its stake in partner Arcellx and expanding the cell therapy alliance the companies started in 2022. The deal expands the lead partnered program to more cancers and gives Gilead a chance at another Arcellx cell therapy candidate made with different technology.

Leads 106
article thumbnail

GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact

MedCity News

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.

article thumbnail

Humana, DUOS Team Up To Support Veteran Seniors

MedCity News

Humana and DUOS have partnered to launch a new program that supports Humana’s Louisiana veteran seniors with a chronic condition. These veterans will be connected to DUOS, which can address their health-related social needs.

77